Chembio Diagnostics is a New York-based company specializing in detecting disease in humans and animals using biomarkers in blood. The company was founded in 1986.
Chembio Diagnostics offers rapid, point of care testing for a range of diseases. Its testing platform is based on chromatographic immunoassay technology which the company calls its Dual Path Platform (DPP). The company filed a patent for its DPP technology in 2005 and was granted the patent in 2007. Chembio Diagnostics holds several other patents related to its DPP technology.
On March 31, Chembio Diagnostics announced the U.S. launch of its rapid serological tests for COVID-19 antibodies. The company says its tests can detect IgM and IgG antibodies and can deliver results in 15 minutes.
Timeline
Further Resources
Chembio launches rapid COVID-19 blood test; shares up 54% premarket
Douglas W. House
Web
April 1, 2020
Chembio, Molecule Holdings launch fingerstick COVID-19 tests - MassDevice
Web
April 1, 2020
